Overview

• The South African Competition Commission stopped its probe into J&J over allegations of excessive pricing.
• J&J will not enforce its secondary patent on bedaquiline, facilitating cheaper, generic versions.
• The decision is expected to improve treatment access for drug-resistant tuberculosis in South Africa.
• Medical advocacy groups have praised the move as a victory against pharmaceutical monopolies.
• South Africa's action may prompt further scrutiny of pharmaceutical pricing strategies globally.